



---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C.

---

**FORM 8-K**

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) January 25, 2008

**BioScrip, Inc.**

(Exact Name of Registrant as Specified in its Charter)

**Delaware**  
(State or Other Jurisdiction of  
Incorporation)

**0-28740**  
(Commission  
File Number)

**05-0489664**  
(IRS Employer  
Identification No.)

**100 Clearbrook Road, Elmsford, New York**  
(Address of Principal Executive Offices)

**10523**  
(Zip Code)

Registrant's telephone number, including area code **(914) 460-1600**

---

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240-14d-2(b)).
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
- 
-

## **TABLE OF CONTENTS**

[Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.](#)

[Item 9.01. Financial Statements and Exhibits.](#)

[SIGNATURES](#)

[Exhibit Index](#)

[EX-99.1: PRESS RELEASE](#)

---

[Table of Contents](#)

**Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.**

On January 24, 2008, BioScrip, Inc. (the "Company") received written notification from the Nasdaq Listing Qualifications Department ("Nasdaq") that the Company had violated the shareholder approval requirement set forth in Nasdaq Marketplace Rule 4350(i); the letter also indicated that the Nasdaq staff had determined that the Company has regained compliance with the Rule and the matter is now closed. The Company violated the above-referenced Rule by delivering to its non-employee directors in May 2007 option agreements for an aggregate of 55,000 shares of Company common stock under a director stock option plan that had expired prior to that date. The Company had previously notified Nasdaq that the option agreements had been erroneously delivered, that the options purportedly evidenced by the option agreements were never granted and that, upon discovery of the error, the Company had cancelled the option agreements.

The Nasdaq letter also requires that the Company issue a press release disclosing receipt of such letter and the Nasdaq rules upon which such letter was based. The Company issued such a press release on January 25, 2008. A copy of the press release, dated January 25, 2008, is attached as Exhibit 99.1 to this report. The exhibit is incorporated by reference into this Item 3.01.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press Release, dated January 25, 2008.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned duly authorized.

Date: January 25, 2008

BIOSCRIP, INC.

By: /s/ Barry A. Posner

Barry A. Posner,

Executive Vice President, Secretary and General

Counsel

---

**Exhibit Index**

99.1 Press Release, dated January 25, 2008.

**FOR IMMEDIATE RELEASE**

**Elmsford, NY — January 25, 2008 — BioScrip, Inc. (NASDAQ:BIOS)**, a comprehensive pharmaceutical care solutions company, today announced that on January 24, 2008, it received written notification from the Nasdaq Listing Qualifications Department (“Nasdaq”) that it had violated the shareholder approval requirement set forth in Nasdaq Marketplace Rule 4350(i); the notice also indicated that the Nasdaq staff had determined that the Company has regained compliance with the Rule and, with the issuance of this press release the matter is now closed. The Company violated the above-referenced Rule by delivering to its non-employee directors in May 2007 option agreements for an aggregate of 55,000 shares of Company common stock under a director stock option plan that had expired prior to that date. The Company had previously notified Nasdaq that the option agreements had been erroneously issued, that the options purportedly evidenced by the option agreements were never granted and that, upon discovery of the error, the Company had cancelled the option agreements.

**About BioScrip, Inc.**

BioScrip, Inc. ([www.bioscrip.com](http://www.bioscrip.com)) (Nasdaq: BIOS) is a specialty pharmaceutical health care organization that partners with patients, physicians, health care payors and pharmaceutical manufacturers to provide access to medications and management solutions to optimize outcomes for chronic and other complex health care conditions.

**Contact**

Stanley G. Rosenbaum  
Executive Vice President and  
Chief Financial Officer  
BioScrip, Inc.  
Tel: 952-979-3768  
Email: [srosenbaum@bioscrip.com](mailto:srosenbaum@bioscrip.com)